Aptorum Group Limited (NASDAQ:APM) Short Interest Down 81.4% in May

Aptorum Group Limited (NASDAQ:APM) saw a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 2,482 shares, a decrease of 81.4% from the May 14th total of 13,376 shares. Based on an average daily trading volume, of 65,802 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Aptorum Group presently has an average rating of “Sell”.

Aptorum Group Stock Performance

Aptorum Group stock opened at $1.12 on Wednesday. The firm has a 50-day moving average of $0.90 and a 200-day moving average of $0.98. Aptorum Group has a one year low of $0.65 and a one year high of $4.47.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.